Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Metabolix considering strategic alternatives

by Alexander H. Tullo
May 23, 2016 | A version of this story appeared in Volume 94, Issue 21

Metabolix, a developer of renewable polyhydroxyalkanoate polymers, is considering a sale of its core polymers business as well as a crop yield technology. The company says it is already in discussions regarding the polymers unit. Metabolix is down to about $5.3 million in cash. It raised $14.7 million from stock offerings in 2015 but burned through $21.9 million that same year. Soon after announcing the potential divestitures, the company signed a licensing agreement with medical device maker Tepha that will garner it a $2 million lump-sum payment.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.